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ABSTRACT
Despite tremendous progress within the field of oncology, highly metastatic forms
of breast cancer remain particularly challenging to effectively treat. Systemically
delivered chemotherapy with cytotoxic agents typically requires some convalescence
time between treatments – allowing rapidly growing cancer types to develop resistance.
Multidrug resistance, also known as pump-dependent, is particularly difficult to treat as it
functions through overexpression of P-glycoprotein, an efflux pump which can produce
resistance to a range of chemotherapeutics.
We have previously developed the cationic micellar copolymer poly(lactide-coglycolide)-g-poly(ethylenimine) (PgP) and demonstrated its capacity as a vector for gene
therapy. Here, we examine the capacity of PgP in mediating co-delivery of siRNA
targeting P-glycoprotein (siMDR1) and the anthracycline class drug doxorubicin to
mitigate multidrug resistance in drug resistant triple-negative human cancer cells in vitro.
The results of this project have shown that PgP can be used to successfully bind siRNA
into a complex that protects from interaction with charged particles through heparin
competition assay, and remains stable in serum conditions. Results of MTT assay
assessing metabolic activity have shown PgP/siMDR1 complexes to exhibit minimal
cytotoxicity in vitro in comparison to untreated human MDA-MB-435 cancer cells.
Assessment of silencing following treatment with PgP/siMDR1 complexes formed at
various nitrogen:phosphate (N/P) ratios has shown significant knockdown of MDR1
mRNA up 67%, in comparison to untreated groups of drug resistant MDA-MB-435 cells.
PgP has also been shown to successfully load the hydrophobic chemotherapeutic
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doxorubicin, improving the toxicity of the drug in vitro. These results show the efficacy
of PgP as a vehicle for delivery of both doxorubicin and siMDR1 to drug resistant cancer
cells, and may have potential for use in co-delivery of siMDR1 and chemotherapeutics in
metastatic cancer treatment. Future studies will include in vivo toxicity and antitumor
studies in athymic mouse breast cancer models.
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CHAPTER ONE
INTRODUCTION & BACKGROUND

In 2005, cancer overtook cardiovascular disease as the leading cause of death in
individuals under the age of 85 in the United States.1 In 2008, an estimated 7.6 million
cancer deaths are thought to have occurred worldwide, with an incidence rate that has
been steadily growing for decades.2,3 Breast cancer in particular accounts for 22.9% of all
cancer occurrences and 14% of cancer related deaths in females, surpassed only by lung
cancer as the cause of female cancer-related mortality,4 with an estimated 255,000 new
cases diagnosed in 2017 in the United states alone and responsible for an estimated
595,690 deaths in 2016.5-7 Advances in early detection methods such as mammography,
Positron emission tomography (PET), and magnetic resonance imaging (MRI) have
significantly reduced breast cancer mortality, (annual mammography alone has shown to
reduce breast cancer mortality by 30% in women 50-69).8 However, the 5-year survival
rate of patients with metastatic breast cancer remains disparately grim at less than 15%,
with a median survival time of 18 months.7,9 Highly metastatic forms of cancer are those
whose comprising cells, rather than remaining relatively contained within a primary
tumor site, have an inordinate ability to migrate throughout the body and proliferate
unchecked. This characteristic makes it very challenging to detect, localize, and
ultimately treat the cancer cells effectively. This disparagingly large gap in treatment
efficacies by stage demonstrates a clear need for more effective means of treating highly
metastatic forms of breast cancer. Intratumoral (IT) administration of chemotherapeutics
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is an obvious solution to the question of how to deliver drugs in cancer treatment, and in
practice reduces systemic toxicity and increases drug action at local site. While common
sense would dictate that this method would be ultimately insufficient for treating
metastatic cancers, recent studies have actually shown that IT therapy can serve to
generate an immune response against subsequent metastases, and when used prior to
surgery on a primary tumor can serve to greatly reduce surgical morbidity or even kill the
primary tumor by itself.10 That being said, some notable shortcomings of IT therapy
include non-uniform distribution, rapid drug clearance, and ultimately low penetration
rates as a result of the high pressure gradients. Overcoming these problems would require
an effective means of both delivering and retaining chemotherapeutics within the tumor
site.

1.1 Metastasis and the Metastatic Niche
Due to the competition inherent in the functionality of biological niches, it seems
unlikely that the small populations of cells involved in initial metastatic seeding would be
capable of producing the quantities of chemokines required for a gradient relevant to that
of the primary tumor, indicating the existence of some additional process operating
synergistically with those addressed above. In addition to the challenge and cost of
investigating the mechanisms of this behavior, previously accepted theories of metastasis
based on Steven Paget’s original ‘seed and soil’ hypothesis offered little to support or
even justify the existence of such a phenomenon.11-13
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As the understanding of metastasis has evolved, however, the identification and
characterization of pre-metastatic and micrometastatic sites arising from Bernard and
Weinberg’s dual proclivity model may serve to explain the tropism of cancer cells to
these sites.14-17 Current understanding places strong association between cancer and with
the widespread mobilization of inflammatory cells in the blood and hematopoietic cells,
however bone marrow derived hematopoietic cells expressing vascular endothelial
growth factor receptor 1 (VEGFR1) and the fibronectin receptor VLA4 (integrin α4β1)
have been found to localize to pre-metastatic sites prior to seeding by cancer cells.18,19
The recruitment of these cells are a result of both tumor secreted angiogenic cytokines
such as VEGFA and placental growth factor (PIGF, which binds to VEGF1), as well as
from S100 inflammatory chemokines and serum amyloid A3 (SAA3) expressed in
response to VEGFA, transforming growth factor β (TGFβ), and tumor necrosis factor-α
(TNF-α) release from the primary tumor.20-22 Sites which also exhibit notably higher
stromal fibronectin expression which, in conjunction with the accumulated myeloid cells,
would serve as effective docking sites for disseminating tumor cells and increase
proliferation of cancer cells at these sites.19,23

1.2 Current Treatment Methods
Current treatment of breast cancer typically begins with an initial surgical
intervention (lumpectomy, partial/full mastectomy, etc.), followed by radiation therapy in
conjunction with either hormone therapy, chemotherapy, immunotherapy, or some
combination of the three. The immediate challenge of surgical intervention is that not all
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forms of breast cancer are easily localized; tumors that do not differ significantly in
density or extracellular composition to the surrounding tissue are very difficult to remove
completely, and highly metastatic forms are unlikely to be entirely localized to a single
tumor.7
Hormone therapy, one of the most common means of treating breast cancer,
functions through antagonistic interaction with hormone receptors that are overexpressed
in cancerous cells, and are understood to play a role in the rapid growth and proliferation
of these cells. The three most well-known of these receptors are those for estrogen,
progesterone, and HER2, and are the targets for most commercially available hormone
therapy drugs24
While effective in treating the roughly 85% of breast tumors that exhibit
overexpression of at least one of these receptors, the mechanism by which this class of
drug functions prevents them from having any therapeutic effect in the 15% of cases
where these receptors are not expressed, commonly referred to as triple negative breast
cancer.25 Highly proliferative and aggressive, triple negative breast cancers are typically
managed by systemic chemotherapy. In addition to high cytotoxicity and a very narrow
therapeutic window, this method of treatment alone is associated with high rates of
recurrence, both local and systemic.26
As possibly the most well-known method of treatment, chemotherapy through the
systemic introduction of cytotoxic agents has long been proven to actively hinder growth
and proliferation of cell populations in advanced breast cancer.27 Anthracyclines, a large
class of chemotherapeutic drugs first developed in the early 1960s, remain among the
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most effective anticancer drugs ever developed (e.g. fluorouracil, doxorubicin,
cyclophosphamide).28 Despite half a century of rapid progress in the field of oncology,
one of the first anthracycline drugs ever developed, doxorubicin (DOX, sold under the
market name Adriamycin), remains on the World Health Organization’s list of essential
medicines and recommended for systemic use in metastatic breast cancer; with demand
such that as recently as 2014 the United States experienced a national shortage.29,30
DOX functions by inducing apoptosis in cells via two distinct mechanisms: (1)
Intercalation into DNA, which inhibits the activity of topoisomerase-II, an enzyme which
is responsible for unzipping the DNA helix. In doing so, all of the cellular processes
dependent on the functionality of topoisomerase-II are subsequently arrested, such as the
replication, repair, and transcription of DNA. Intercalation can also result in histone
eviction from transcriptionally active chromatin, further deregulating the DNA damage
response in DOX exposed cells. (2) Cytosolic conditions equilibrate the oxidation of
Doxorubicin to semiquinone in a reversible reaction that serves to produce reactive
oxygen species capable of significantly damaging cellular DNA.31,32
Occurring simultaneously within a cell, these mechanism cause DOX and other
similarly functioning anthracyclines to exhibit potent apoptosis-inducing qualities.
However, a number of serious limitations still exist that can severely hinder the
effectiveness of clinical treatments dependent on the use of these agents. Depending on
the drug, these limitations can include poor retention, non-specific distribution, toxicity,
and the development of resistance in cancer cells.34-36 In fact, the cytotoxic characteristic
of these agents that makes them so effective in mitigating the proliferation and growth of
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cancerous cells is the very reason why cytotoxic chemotherapeutics alone will never
prove to be the oncological panacea. This is due to the fact that cytotoxic agents currently
available have no mechanism for selectivity; they affect cancerous and healthy cells
indiscriminately. The severe side effects of chemotherapy are a result of the drugs
functioning properly; the cell killing effects of the chemo drugs being active only on
cancerous cells as well as the healthy cells in bone marrow, gastrointestinal epithelia, hair
follicles, and cardiac musculature.37
The damage on healthy cells caused by the action of these drugs results in the need
for convalescence time between treatments, to allow for recovery of the population of
these affected healthy cell types. Anthracycline-based regiments have objective response
rates of 50-80%, with median response duration and survival times lasting from 10-18
months and 18-26 months, respectively.9 The contrast between the purported efficacy of
these drugs and the clinical data is likely indicative of the use of suboptimal doses and
longer than ideal convalescence times between treatments to prevent acute/chronic
toxicities and minimize damage to non-cancerous tissues.38 Due to the heterogeneous
populations of cancer cells in tumors, especially fast growing tumors, this method of
treatment fosters the rapid transition from a primarily drug sensitive population to an

Figure 1. Schematic Representation of Resistance Acquisition in Cancer Populations by Cyclic Chemotherapy. After
the first round of chemotherapy, cell population decreases significantly due to the death of sensitive cancer cells.
Recovery time between chemotherapy sessions allows resistant cells to grow and take over the entire population
(Orange: drug sensitive cells, Pink: drug resistant cells).33
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entirely resistant population (Fig. 1). In many cases, the mechanism of the resistance
acquired causes diminished efficacy in a range of drugs, often requiring the use of
multiple chemotherapeutic agents with very different mechanisms of action over the
course of treatment.39
1.3 Multidrug Resistance
There are two main pathways by which a population of cancer cells can become
multidrug resistant (MDR), one being pump dependent and the other being non-pump
dependent.40 Non-pump dependent MDR is characterized by an upregulation of proteins
that inhibit the apoptotic pathway; Bcl-2 being the most commonly observed in this form
of drug resistance.41 Since most common chemotherapeutic drugs such as doxorubicin or
paclitaxel function within the cell by triggering apoptosis, non-pump dependent MDR
can retard or even eliminate the efficacy of drugs while still facilitating an environment
promoting the development of pump-dependent resistance.42
Pump dependent MDR is characterized by an overexpression of P-glycoprotein 1,
also known as multidrug resistance associated protein 1 (MDR1), a transmembrane drug
efflux pump that functions to rapidly expel therapeutic agents from the cytosol into the
extracellular domain before they can reach their site of action. This overexpression of
MDR1 results in both a diminished efficacy of the drug and an increase in extracellular
toxicity,42 and has been found to be a major contributor to chemotherapy failure in
different MDR-overexpressing cancer types.43-45 This mechanism of drug resistance is
particularly effective since, once developed, it can remove a wide range of drugs
indiscriminant of their mechanism of action. While the use of drugs functioning via an
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alternative mechanism of action has shown to be an effective method of mitigating the
action of non-pump dependent resistance, overcoming pump dependent MDR has shown
to require more complex methods of treatment, involving either drugs with a novel
mechanism of inhibiting activity of efflux pumps, or some means of preventing
expression of the genes coding for them.46 In order to most effectively overcome drug
resistance in cancer populations to allow for successful long-term treatment with
cytotoxic agents, simultaneous inhibition of both mechanisms must occur.47,48 Lastly, cotreatment of cancer cells exhibiting MDR with siRNA-mediated gene silencing and
chemotherapeutic drugs, administered separately, has shown to improve the overall safety
and efficacy of treatment, however it is very likely that co-delivery of resistanceinhibiting siRNA with chemotherapeutic drugs would be more efficient in treating cancer
cell populations exhibiting MDR.36, 49
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CHAPTER 2
GENE THERAPY IN CANCER TREATMENT

Gene therapy has shown great promise in treating gene-related disorders. Since the
first successful clinical trial in 1990 treating Adenosine Deaminase Deficiency (ADA),50
research in gene therapy has exploded from rare monogenic diseases to include potential
applications in the treatment of complex conditions like cancer.51 Typical gene therapy
approaches can be divided into two major categories based on action: function enhancing
(such as through introduction of pDNA), and function inhibiting (such as gene silencing
through RNAi). Gene silencing through RNA interference (RNAi), can effectively inhibit
the expression of nearly any gene with high efficiency and specificity, and in doing so
stop production of target proteins regardless of their function or structure.

2.1 Function Interference
The RNAi pathway is initiated by the presence of long double stranded RNA
(dsRNA) (>200 base pairs) in the cytosol, which activates the enzymatic complex Dicer.
The dsRNA is then processed and cleaved by Dicer into twenty-two double stranded
fragments (20-25 base pairs) of small interfering RNA (siRNA) with a two nucleotide
overhang on the 3’ ends of either strand. The dicer products then assemble with
complexes containing endoribonuclease, which makes up the RNA-induced silencing
complex (RISC), at which point the RNA strands separate, with the sense strand
remaining in the cytosol to be degraded and the antisense strand remaining bound RISC,
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activating the complex. Once activated, the RISC then identifies, binds, and cleaves any
messenger RNA (mRNA) complimentary to the antisense strand bound to the RISC,
preventing translation and selectively silencing gene expression.52,53
Long dsRNA can be delivered to initiate the RNAi pathway, however the use of long
dsRNA for gene therapy has been shown to present a number of delivery challenges.
These challenges include transport through the plasma membrane, protection from serum
nucleases, and preventing immunogenesis, all of which would make actual
implementation in a therapeutic application impractical.54 Synthetic siRNA, however,
bypasses several of the challenges of long dsRNA due to its reduced size, such as easier
encapsulation in small delivery vehicles, and reduced immunogenicity.55,56 It is likely
due to these reasons that siRNA is most common structure used in RNAi-based
therapeutics.53
In most studies attempting to use gene therapy in the treatment of cancer, target
genes involved in the apoptotic or proliferative pathways are exploited to improve
efficacy of adjuvant therapies.57 These have included function enhancing approaches
delivering pDNA coding for proapoptotic genes such as TNF-α58 and p53,59 as well as
function inhibiting approaches, delivering siRNA targeting antiapoptotic or resistancemediating genes such as Bcl-260 and MDR proteins.61 In particular, studies examining
siRNA-mediated silencing of MDR proteins have shown some success in re-sensitizing
cells to chemotherapeutics and improving treatment with anticancer drugs.62-65 That being
said, few products have made it as far as clinical trials this far,66 often due to issues
challenges of siRNA delivery.
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2.2 Barriers to Treatment
Gene therapy utilizing the RNAi pathway has enormous potential for clinical
application; however, several major physiological barriers stand in the way of an
effective siRNA-based therapeutic reaching the market anytime soon. In order to have
any effect on gene expression, siRNA molecules must be delivered directly to the cytosol
of target cells. Injection of naked DNA/RNA has been empirically shown to be fairly
ineffective as a means of drug delivery within this field; the large size, negatively charge
phosphate groups, and relative hydrophilicity all present immediate challenges
individually capable of preventing nucleic acids from diffusing through cell membranes
under normal conditions (e.g. passive diffusion), meaning that a delivery system that can
selectively and efficiently deliver a gene to target cells is needed for successful gene
therapy to occur.
In addition to mediating endocytosis, an effective delivery system must be able to
overcome (among others) several major barriers to successful gene silencing in vivo.
These include: (i) a means of specificity, both in biodistribution as well as cellular
uptake; (ii) protection against degradation by serum ribonucleases; (iii) preventing and
delaying particle/siRNA clearance through the renal and reticuloendothelial systems; (iv)
a mechanism to avoid or at the very least minimize interaction with serum proteins and
non-target cells (it is in this regard, primarily, that bPEI falls short in satisfying all the
requirements of an effective gene carrier); (v) minimization of complex immunogenicity
and cytotoxicity in systemic circulation, and finally, (vi) to facilitate delivery into the
cytosol of cells within the target population.53
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Another major barrier to the delivery of siRNA in vivo is the need for particle
protection in systemic circulation – be it from ribonucleases, serum proteins, non-target
cell interactions, elution, or targeting by the immune system. Ribonucleases present in the
blood will rapidly degrade free nucleic acids unless otherwise shielded from them. While
this can be overcome through sheer volume of systemically introduced RNA or DNA,
this process is far too inefficient for clinical application and can initiate an immune
response, therefore a means of protecting the siRNA while in circulation is necessary.67
Additionally, any non-native particles such as free nucleic acids also stand the risk of
aggregation with serum proteins and non-target cells. Loading and protection from
degradation of siRNA could be accomplished relatively easily via covalent binding or
encapsulation within the particle, however the former of these methods would be
unsuitable for siRNA mediated gene silencing due to its mechanism of action – free
siRNA must be present within the cytosol of target cells to initiate assembly and
activation of RISC. Therein lies one of the more complex aspects of delivering nucleic
acid as opposed to traditional therapeutics – the siRNA must be bound to a vector such
that it remains associated and protected by the particle in circulation, while readily
dissociating from the complex once in the cytosol.68
One potential method of binding siRNA to a particle that would allow this to occur is
through electrostatic interaction, possible due to the strong negative charge associated
with nucleic acids as a product of the contained phosphate groups. Complexation via
electrostatic interaction with positively charged compounds would have the potential to
facilitate both an appropriate binding strength and a means of spontaneous complexation.
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While degradation by serum ribonucleases is a fairly simple challenge to overcome
through the use of an appropriate drug delivery vehicle, the avoidance of protein binding
has proven to require a more complex solution. With regards to opsonins of the adaptive
immune system (e.g. antibodies) and cells of the innate immune system, overcoming this
barrier has proved a challenge within the field of drug delivery for decades, with limited
success.69 One of the most common methods of mediating protein binding (and
subsequently opsonization) of nanoparticles is through the conjugation of a shielding
group to the outer surface of the polymer. Some examples of shielding groups that have
been heavily tested include polyacrylamide, poly(vinyl alcohol), and poly(N-vinyl-2pyrrolidone), however more recent studies have shown a clear preference to utilize
polyethylene glycol (PEG), and PEG-containing copolymers.70-72 As evident by the
examples listed, these shielding groups tend to be non-ionic surfactants with long
hydrophilic polymer chains, which function to mediate protein binding through the
formation of a hydration shell around the particle.70 In doing so, PEGylation can
dramatically increase retention time in systemic circulation by effectively ‘hiding’
particles from serum proteins that would otherwise bind to them and target them for RES
uptake.73,74 This has shown to be very effective, largely due to the fact that hydrophobic
and electrostatic interactions are the primary forces involved in protein adsorption.75
Despite the advantages associate with the use of cloaking polymers such as PEG, its
incorporation onto nanoparticles for gene therapy presents several drawbacks as well.
The effectiveness of PEG in surface charge shielding and preventing protein adsorption is
also likely the cause of reduced complexation with nucleic acids shown in particles that
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have been PEGylated, as well as diminished endocytosis and transfection efficiency.39,76
More recent studies have also begun to indicate that PEG may in fact be more
immunogenic than previously thought, which would challenge the candidacy of the
polymer for use in long-term treatments.77
As mentioned, many barriers exist to siRNA delivery that do not require attention
in the delivery of pDNA. Despite all their similarities, pDNA and siRNA behave very
differently due to some important differences. Stability is a major concern with RNA,
which are vulnerable not only to base-catalyzed hydrolysis by their 2’-OH groups and the
ribonuclease abundant in biological environments, but as siRNA are also susceptible to
auto-hydrolysis at the 3’ overhangs necessary for optimal function.78 Another major
difference that could have serious implications in behavior is size. The radically smaller
size of siRNA, with a typical length of 18-25 bp, in comparison to pDNA, which could
range anywhere between 1 and 200 kb,79 could result in very different behaviors in both
drug delivery vehicles (DDVs) and a physiological environment– especially because their
length is directly linked to overall charge. These factors must be kept in consideration
when attempting to translate a vehicle previously used in pDNA delivery to that of
siRNA
2.3 Nanoparticles in Drug Delivery
To first focus on specificity of delivery, while in systemic circulation an effective
drug delivery vehicle must facilitate deposition within a specific area of activity- in the
case of cancer this almost always means particle accumulation within a tumor or tumors.
In this regard, the utilization of nanoparticles for drug delivery has a marked advantage
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over other methods due to the utilization of the enhanced permeability and retention
(EPR) effect as a means of passive targeting. The EPR effect is an intrinsic characteristic
of colloidal particles in circulation, in which they exhibit systemic circulation times
significantly higher than would otherwise be expected, and therefore an increased
bioavailability and ability to permeate specific bodily tissues such as tumors.80 This effect
is observed in particles with a diameter between approximately 10-100 nanometers, a size
range at which the particles are too large for rapid elution through glomerular filtration by
the renal system, while at the same time remaining too small for efficient identification
and opsonization by the reticuloendothelial system (RET).81,82 The growth process and
subsequent structure of tumors serves to create a number of important physiological
characteristics that ultimately compound the impact of the EPR effect when used in
oncological applications. Rapid angiogenesis, a hallmark of advanced and aggressive
cancers, occurs during the both initial formation and tumor growth, as the high nutritional
demands of the rapidly proliferating cells produce an environment that too hypoxic and
nutrient-deficient to support themselves via diffusion at more than 1-2 mm removed from
a blood supply.83-85 They respond to this deficiency by secreting a range of angiogenic
growth factors, recruiting nearby vasculature to produce a huge network that due to rapid
formation and chaotic cell growth is inefficient and disorganized.84 The poorly developed
vascular junctions within this system are highly discontinuous.85 These openings allow
for the passage of particles that are too large to pass through any smaller endothelial
junctions such as the fenestrations of renal endothelium, much less the minute gap
junctions of normal healthy vascular endothelium. This is significant in that the
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circulating nanoparticles will be capable of not only highly permeating the tissue of
tumors, but also doing so in a significantly higher degree relative to healthy tissues –
thereby introducing a favorable degree of specificity with regards to particle
biodistribution.86 Another unique characteristic of tumors is the incredibly poor
hemodynamics, which arise partly from their poorly organized blood supply and partly
from the complete lack of lymphatic drainage systems found in tumors. In the case of
nanomedicine and EPR effect, this hemodynamic property serves to further encourage the
retention of particulates within the previously specified size range.88
2.4 Current Strategies
The use of nanoparticles for application in clinical medicine is a practice that has
been heavily researched since the early 1970’s, and has led to the development of a
plethora of particle designs, varying wildly by size, composition, structure and function.
Of that selection, there are two overarching classes of nanoparticle primarily considered
as potential vectors for gene therapy: viral and non-viral vectors. Both of these carrier
types have several subclasses with their own strengths and weaknesses that must be
considered and weighed in relation to the application.
Viral vectors are created through the use of a functional virus, in which the genes
encoding a therapeutic protein have been inserted into a viral capsule so as to express the
therapeutic RNA endogenously, while removing the genes responsible for viral activity
that would be detrimental to the patient, such as viral DNA synthesis, and the production
of reverse transcriptase/integrase.89 Academic interest in viral vectors has waned over the
last decade however, likely due to the severe potential drawbacks and the little-
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understood mechanisms behind them. Once a heavily researched topic, viral vectors have
a number of advantages in comparison to non-viral alternatives including the potential for
long-term expression of the target gene from only a single injection.90 Additionally, this
biologically-derived approach builds upon thousands of years of evolutionary progress to
the purpose of delivering genetic material to host cells, the result being a vector that is
incredibly effective at transfecting even non-dividing cells such as those of the central
nervous system.91
While highly infective, many viral capsules are seriously limited by size, impacting
their ability to deliver more complex RNA sequences.92 Adenoviral vectors, which have a
fairly large capacity relative to other viral vectors and a linear double-stranded DNA
genome, have proven to be applicable and actually quite effective in RNAi delivery.89
Unfortunately, Adenoviral vectors also have the potential to elicit a strong immune
response and liver toxicity.93 Adeno-associated viruses (AAV) have also been explored as
vectors for gene therapy due to the fact that unlike the larger adenoviral vectors, AAV’s
are non-pathogenic to humans, however they are also significantly smaller (~5.2 kB) and
like adenoviral vectors are only transiently expressed.94,95 As long-lasting vectors capable
of integration into a host’s genome, vectors produced from Retroviral and lentiviral (a
subclass of retrovirus) sources have shown huge potential in the treatment of genetic
disorders and even in suppression of diseases such as HIV-1, however like adenoviral
vectors, serious concerns exist regarding the safety of these vectors.95,96 In summary,
viral vectors have been shown to have huge potential in gene therapy applications,
however a number of limitations present in all viral vectors regardless of subclass must
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first be addressed, including limited loading capacity, immunogenicity, and risk of wildtype virion regeneration.97-99
Non-viral vectors for gene therapy are artificially produced carriers designed to
assemble with siRNA to form complexes capable of delivering their complex genetic
material to the cytosol of target cells. While much safer than their viral alternatives, nonviral vectors come with their own drawbacks.68 Non-viral vectors have an effect that is
inherently transient, and unlike viral vectors, they must address challenges such as
mediating particle endocytosis and endosomal escape in the design of the particle.
Subclasses of non-viral vectors include, among others, liposomes, lipoplexes, and
cationic polymers.
Liposomes are highly ordered nanoparticles that are composed of a lipid bilayer
envelope which encapsulates an internal aqueous phase. In many ways liposomes are
biomimetic structures, very closely resembling the phospholipid bilayer of the plasma
membrane in cells. Liposomal nanoparticles have long been used for applications in drug
delivery, having proven to be especially effective in delivering hydrophilic drugs via
encapsulation within its aqueous core. Other notable advantages of using liposomes for
drug delivery are its low cytotoxicity, ease of surface modification, and potential for selfassembly.100 Unlike other non-viral vectors for gene therapy, liposomes can be loaded
with siRNA just as easily as with any hydrophilic drug – in many cases by simply mixing
solutions of the two components – loaded safely within the cell simply by
encapsulation.100 Some drawbacks of liposome use for gene therapy include poor
transfection efficiency and the lack of any means of mediating endocytosis or endosomal
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escape, as well as a high risk of opsonization. However, these can be overcome via
surface modification with other bioactive compounds capable of addressing these
challenges.101
Similar in composition to Liposomes, lipoplexes are formed when cationic lipids
electrostatically complex with nucleic acids to produce a stable molecule capable of
binding and protecting siRNA in systemic circulation.102 The use of cationic lipids
provides several advantages over uncharged liposomes, the foremost being its ability to
spontaneously associate with siRNA and the lipid bilayer of cells. This results in much
higher cell internalization, both by endocytosis and by disruption of the cell’s plasma
membrane (PM). The presence of a strong positive surface charge on these particles also
has the potential to increase cytotoxicity, as well as phagocytosis/capture via the RES,
which can drastically reduce residence time.103,104
Cationic polymers, like cationic lipids, also spontaneously complex with siRNA due
to ionic interactions between the cationic groups within the polymer and the phosphate
groups of the siRNA to form a stable particle, with many similar properties to lipoplexes.
Excessively high surface charges in these vector designs can result in high cytotoxicity
and even spontaneous aggregation with abundant negatively charged blood proteins such
as albumen and fibrinogen, which typically results in the rapid elimination from systemic
circulation.81 While charge shielding could be accomplished via conjugation with stealth
polymers, a major advantage of using cationic compounds to bind and deliver anionic
nucleic acids is that the final surface charge of the complex is a function of the ratio
between the protonated amine groups in the carrier’s structure and the negatively charged
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phosphate groups of the bound nucleotides. This ratio is commonly described by the N/P
ratio, and can be optimized based on the specific vector being examined. This system
allows for the optimization of particle loading in terms of balancing toxicity and
transfection efficiency. With exceptions to polymers conjugated to targeting moieties,
most cationic polyplexes facilitate intracellular uptake by nonspecific endocytosis
through interaction with heparin sulfate proteoglycans (HSPGs) present in the
extracellular matrix.105 For this reason, polyplexes that maintain a slightly positive
surface charge usually show improved stability and interaction with cell
membranes,106,107 however this charge can also produce certain undesirable effects when
used in vivo such as serum protein induced aggregation and excessive interaction with
plasma membranes.108
One well-known example of a cationic polymer used in polyplex formation is
polyethylenimine (PEI). PEI is considered to be the ‘gold standard’ of non-viral gene
delivery due to its high cellular uptake and endosomolytic activity, both essential aspects
of transfection.109,110 While low molecular weight (MW) PEI variations have been
investigated and found to have a somewhat lower cytotoxicity, high MW (25 kDa) PEI is
much more commonly seen in studies investigating cationic polyplexes for gene therapy,
likely due to its significantly higher transfection efficiency.39,111-113 This is because high
MW PEI is incredibly effective in mediating both endocytosis and endosomal escape,
two of the most challenging barriers to overcome with non-viral vectors. The branched
version of PEI in particular (bPEI) has been shown to have highest efficiency and
cytotoxicity – a result of the presence of primary amines throughout the branched
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variation and their affinity for protonation at physiological pH compared to the secondary
amines comprising linear PEI (lPEI) (for the remainder of this paper, it can be assumed
that PEI is in reference to high MW bPEI unless otherwise specified).114,115 Other popular
cationic vectors for siRNA delivery include polyamidoamine (PANAM) dendrimers,
polylysine (PLL), and chitosan, however like PEI these polymers have not seen much
success in vivo due to similar issues with efficiency and toxicity in biological
conditions.106,116,117
2.5 Endocytosis and the Proton Sponge Effect
While PEI has been reported to enter the cell via a combination of mechanisms
partially dependent on particle size, having been documented entering cells through
clathrin and caveolin-mediated endocytosis as well as macropinocytosis, recent studies
have shown that these mechanisms are not solely responsible for all PEI endocytosis.118120

One proposed hypothesis to account for this finding, as well as the synergistic effect

of cationic charge on siRNA delivery is that ionic interactions between the cationic
polymer (such as PEI) and the PM result in the transient disruption of the PM to create
nanoscale holes capable of permitting particle transport into the cell.121 Interestingly
enough, the same interaction between cationic polymers and the outermost bilayer has
been proposed by several research groups as the cause of the cytotoxicity seen in cationic
polymers.122,123 While particles entering the cell through this proposed mechanism would
be safe from endosomal degradation, the high transfection efficiency of PEI compared to
other cationic polymers indicates the action of another mechanism at work – endosomal
escape.
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Endosomal escape is a critical function of an effective gene carrier, as it can
dramatically improve transfection.124 Failure for endosomal escape to occur would
otherwise result in complex degradation from the acidic environment as well as the
proteases and peroxidases that accumulate as the early endosome reaches maturation.125
The most commonly accepted mechanism that has been proposed to explain PEI’s
apparent ability to escape the early endosome is known as the “proton sponge” effect,
hypothesized to occur with other cationic polymers such as PAMAM and chitosan, and
utilize the buffering capacity of tertiary and secondary amine groups to inhibit endosomal
acidification. The theory proposes that as the pH begins to drop in the early endosome,
protonation of amine groups in the polymer that exhibit pKa values between neutral and
lysosomic pH inhibits further acidification of the endosome. While reports from
Benjaminsen et al. have indicated that this is not in fact the case, and that the endosome
eventually reaches a normal pH not below 5.5,126,127 this is not to say that his results
invalidate the theory – in fact Benjaminsen and Richard et al. both argue that these results
simply indicate that while functioning as a ‘proton sponge,’ the V-ATPase pump
responsible for stabilizing the pH of the endosome is capable of overcoming this
effect.126,127 In any case, the buffering capacity of the PEI results in the influx of protons
to the endosome by the V-ATPase pumps in the process of stabilizing endosomal pH.
The presence of both free protons and the protonated primary and secondary amine
groups within the PEI result in the formation of an electrochemical gradient responsible
for the endosomal transport of large chloride ions into the endosome, in turn creating an
osmotic gradient responsible for the influx of water into the endosome. The influx of
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these protons, counter-ions, and water result in the swelling and ultimately rupturing of
the endosome, releasing its contents into the cytosol.128,129 Once taken up by a target cell
and exposed to the acidic conditions, the siRNA should be able to disassociate from the
complex and diffuse throughout the cytosol.130
2.6 Poly(ethylenimine) and Strategies for Improvement
While touted as the gold standard of non-viral vectors in gene delivery, there still
exists a significant gap between PEI’s impressive efficiency in non-serum conditions and
its relative ineffectiveness in serum conditions.131,132 Most likely this is a result of particle
stability being less than ideal, the polymer strands comprising the complex readily
aggregating to the abundant anionic serum proteins or erythrocytes in the blood.133 This
explanation for the performance of PEI seems reasonable when considering the ionic
interactions of the nucleic acids and the cationic polymer are the only forces holding the
complex together.68 PEI’s poor serum performance being a result of complex instability
is further supported by the drop in transfection efficiency and aggregation observed in
lyophilized samples as well as samples diffused out of hydrogel-based scaffolds.134-136
One promising method of improving cationic polyplex stability that has been investigated
is grafting with hydrophobic polymers. In addition to improving colloidal stability, the
use of amphiphilic block copolymers for complexation with nucleic acids has been shown
to increase transfection efficiency and decrease cytotoxicity.131,137,138 Specifically, vectors
that assemble into a micelle formation through incorporation of hydrophobic polymers
also have shown to reduce charge density and improve the particle’s capacity to facilitate
endosomal escape.139 In the specific case of bPEI, one of the most effective modifications
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of the polymer to date has been accomplished by conjugation with low MW hydrophobic
groups.140 Micelle formation is primarily driven by two highly cooperative forces:
hydrophobic interactions between the hydrophobic regions of the amphiphilic polymer,
and electrostatic attraction between the negatively charged nucleic acids and the cationic
regions of the polymer.141, 142 Micelles will form spontaneously at or above the critical
micellar concentration (CMC), and have shown to contribute heavily to particle
stability.143
Having established the need for effective drug delivery systems for the application of
both chemotherapeutics and nucleic acids, as well as the advantages of co-delivery over
just concurrent treatment, the need for a multifunctional vector capable of specific and
combinatorial delivery of these therapeutic agents is quite apparent.144 While this particle
would necessarily be used in adjuvant treatments, the successful implementation of such
a complex could represent a sorely needed advancement on current treatments.
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CHAPTER 3
RESEARCH AIMS

3.1 Objectives
While many advances in oncology have improved patient outlook and overall
mortality, the development of multidrug resistance remains a critical obstacle in the
development of treatments in breast cancer. The goal of this research is to develop a dualfunctional nanotherapeutic for the mitigation of multidrug resistance in metastatic breast
cancer. This study is designed around the hypothesis that combinatorial therapy with
doxorubicin and siRNA silencing P-glycoprotein will serve to concurrently re-sensitize
drug resistant cells to critical chemotherapeutics while delivering said drug to the newly
sensitized cells. This study will focus on in vitro analysis of both doxorubicin and
siMDR1 delivery to cells as mediated by PgP.

3.2 Vehicle Design
The cationic micellar copolymer Poly(lactide-co-glycolide)-graftpoly(ethylenimine) (PgP) is a novel design (figure 2) synthesized by conjugating the
cationic polymer PEI to the hydrophobic block copolymer PLGA, creating a structure
that should retain the characteristics of PEI that made it such a promising vehicle for gene
therapy – namely its ability to electrostatically bind and intracellularly delivery nucleic
acid, as well as its buffering capacity within early endosomes. A major barrier of PEI to
use in therapeutic applications is its relative inability to function in serum conditions due
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to issues of stability and interaction the charged particles present in high protein
conditions. By conjugating the polymer to PLGA, the produced particle should exhibit
improved stability due to hydrophobic interactions and the spontaneously arising micellar
structure of the particle at concentrations above the critical micellar concentration
(CMC). The hydrophobic PLGA core should be capable of loading hydrophobic drugs
while providing stability to the particle, with the PEI in the corona of the micelle being
able to electrostatically bind nucleic acids such as pDNA or siRNA due to the presence of
cationic amine groups. The complexed particle size has been characterized at a diameter
of approximately 120 nm, within optimum range for exploitation of the EPR effect –
being too large for rapid expulsion by glomerular filtration but too small for targeting by
opsonization and elimination by the reticuloendothelial system – while passively
targeting and accumulating in tumorous tissue as a result of the poor hemodynamics and
endothelial disfunction arising from their rapid and disorganized growth. Once
accumulated, it can be endocytized, facilitating endosomal escape into the cytosol via the

Figure 2. PgP Micelle Design. The micellar structure of PgP, where black lines represent the PLGA blocks and
red lines represent PEI chains within the PgP polymer.
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proton sponge effect – an inherent characteristic arising from the buffering capacity of
secondary amine groups within the PEI branches. Once in the cytosol, their nucleic acid
load can begin to function, and the action of any loaded anthracycline-class
chemotherapeutics will be drastically be improved by delivery to the site of action.

3.3 Study Outline
In order to determine the ability of PgP to function as designed, the suitability of
PgP as a delivery vehicle for both siRNA and hydrophobic chemotherapeutics must be
examined. The stability of PgP/siRNA will be assessed, as well as its ability to function
in vitro in simulated physiological conditions (i.e. in serum). Initially, this will be
determined by testing the ability of PgP to transfect MDA-MB-435 ADR and wild type
cells with pGFP, as well as the cytotoxicity of the polymer in both cell types. Should the
initial results show PgP to be an effective vector for pDNA delivery with minimal
toxicity in this cell line, stability can be determined by heparin competition assay to
determine the stability of the PgP/siRNA micelles in competition with other charged
particles, as well as the stability of siRNA-bound complexes relative to the pGFP-bound
complexes, which have already been shown to be effective in transfection of other cell
lines. This will be followed by in vitro analysis of both cytotoxicity and its ability to
successfully silence the MDR1 gene, on both the mRNA and protein level, in MDA-MB435 ADR cells when complexed with siMDR1. Doxorubicin loading in PgP will also be
assessed, through photospectrometry to determine loading efficiency, and then
cytotoxicity by MTT assay of MDA-MB-435 ADR cells treated at varying concentrations
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to determine the optimum loading concentration. Finally, the practical efficacy of codelivering doxorubicin with siMDR1 will be assessed by cytotoxicity studies of both codelivered siMR1 and doxorubicin in the form of DOX/PgP/siMDR1 complexes. Future
studies can include in vivo antitumor, biodistribution, and toxicity studies in athymic
nude mice using induced MDA-MB-435 ADR tumors and intratumoral treatment with
the fully loaded and complexed particle.
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CHAPTER 4
MATERIALS & METHODS

4.1 Materials
Poly(lactide-co-glycolide) (PLGA, ~4 kDa 50:50) was purchased from Durect
Corporation (Pelham, AL), with a carboxylic end group. Branched poly(ethylenimine)
(PEI, 25 kDa), as well as Thiazolyl Blue Tetrazolium Bromide, and RPMI 1640 was
purchased from Sigma-Aldrich (St. Louis, MO). The wild type (WT) and Doxorubicinresistant (ADR) MDA-MB-435 cells were provided by Dr. Hassan Uludag’s group at the
University of Alberta (Alberta, Canada). FBS was acquired from Atlanta Biologicals
(Norcross, GA). 200 nM L-Glutamine, as well as 0.25% trypsin/2.21 mM EDTA in
Hank’s Balanced Salt Solution were purchased from Mediatech Inc. (Manassas, VA).
Doxorubicin (DOX) was purchased from LC Laboratories (Woburn, MA). Doxorubicin
Hydrochloride (DOX-HCl) was purchased from MP Biomedicals LLC (Solon, OH).
Formaldehyde Loading Dye used in gel electrophoresis was purchased from Ambion Inc.
(Waltham, MA). Molecular weight ladders (1 kb and 100 bp DNA Ladders), and
Penicillin/Streptomycin (10,000 units/mL Penicillin, 10 mg/mL) were purchased from
Gibco (Grand Island, NY). Plasmid DNA encoding the Monster Green Fluorescent
Protein (pGFP) was purchased from Promega (Madison, WI). The siRNA targeting
MDR1 (ABCB1 or P-glycoprotein, NCBI reference sequence: NM_000927.4), ID 4123
and Negative Control 1 siRNA (siNT) were obtained from Ambion Inc. (Waltham, MA).
The TURBO DNA-Free Kit, HALT Protease & Phosphatase Inhibitor Cocktail, Pierce

29

BCA Protein Assay kit, SuperSignal West Pico Chemiluminescent Substrate, HighCapacity cDNA Reverse Transcription kits, 6x DNA Loading Dye, Albumin Standards,
and the Lipofectamine 3000 used as a positive control in transfection, were all obtained
from Thermo Fisher Scientific (Waltham, MA). Mouse monoclonal anti-β-actin antibody
(1:1,000) and mouse monoclonal anti-MDR1 antibody (1: 1,000) was purchased from
Santa Cruz Biotechnology (Dallas, TX). Goat anti-mouse HRP-conjugated antibody was
purchased from Southern Biotechnology (Birmingham, AL). 4x Laemmli Sample Buffer,
Immuno-Blot PVDF membranes, Molecular Biology Agarose, and Precision Plus Protein
Kaleidoscope Protein Standards used in western blotting were purchased from Bio-Rad
Laboratories (Hercules, CA). RNeasy Mini Plus RNA isolation kit, Quantitect SYBR
Green PCR kit, and Maxi Plasmid DNA Purification kits were purchased from Qiagen
(Valencia, CA). Primers for RT-PCR were custom designed and purchased from
Integrated DNA Technologies (Skokie, IL), with sequences as given: Forward Human
GAPDH 5’- CAC CCA CTC CTC CAC CTT TG -3’ Reverse Human GAPDH 5’- CCA
CCA CCC TGT TGC TGT AG -3’ Forward Human MDR1 5’- TCG CCT GGA TTC
CCT CCT C -3’ Reverse Human MDR1 5’- AGG TCA GCA GAG CCA AGG AG -3’

4.2 Synthesis of Poly(lactide-co-glycolide)-g-poly(ethylenimine)
The Cationic and amphiphilic copolymer poly(lactide-co-glycolide)-gpoly(ethylenimine) (PgP) was synthesized according to methods previously described by
Gwak et al, in which 4 kDa Poly(lactide-co-glycolide) (PLGA, 50:50) containing a
carboxylic end group was conjugated to the primary amine group of 25 kDa
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polyethylenimine, branched, (bPEI) by ester bonding. Once synthesized, the produced
PgP was then purified through dialysis against deionized water using a membrane filter
with a molecular weight cut off (MWCO) of 50 kDa. To remove any unreacted PLGA
precipitate present the PgP was then centrifuged for 10 minutes at 5,000 rpm. The
purified PgP was then lyophilized and stored at -20 °C.
Structure and molecular weight of PgP was confirmed by 1H-NMR and gel permeation
chromatography (GPC), respectively, as previously described.132

4.3 Plasmid Amplification and Purification
The plasmid encoding Monster Green Fluorescent Protein (pGFP) was obtained
from Escherichia coli DH5α Transformed and amplified in Lysogeny broth on a shaker
plate at 250 rpm for 12 hours at 37 °C. The Endofree Maxi Plasmid Purification Kit was
used to isolate and purify the plasmid according to the manufacturer’s protocol. Purity
and concentration of pGFP was determined via spectrophotometry using the Biotek
Synergy HT plate reader.

4.4 Cell Culture
The human cell line MDA-MB-435 (both WT and ADR) were cultured in RPMI
1640 cell medium supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillinstreptomycin (p/s), and 1% L-Glutamine at 37 °C and 5% CO2. Drug resistance in MDAMB-435 ADR cells was maintained through weekly treatments of 0.2 μg/mL DOX-HCl.
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4.5 Transfection Efficiency and Cytotoxicity of PgP/pGFP Complexes
4.5.1 Transfection Efficiency of PgP/pGFP polyplexes
Transfection efficiency of PgP/pGFP polyplexes was determined by transfection
of MDA-MB-435 ADR and WT cells with PgP/pGFP complexes, followed by analysis
with fluorescent imaging and flow cytometry.
MDA-MB-435 cells (1.2 x105 cells/well) were seeded in 12-well plates
containing 1 mL of complete media and cultured for 24 hours. Media was then aspirated
and replaced with RPMI 1640 supplemented with 10% FBS and 1% L-Glutamine, and
PgP/pGFP complexes added. PgP/pGFP complexes were prepared immediately prior to
transfection, and were formed at N/P ratios of 30:1, 45:1, and 60:1 in sterile deionized
water and incubated for 30 minutes at 37 °C. Controls used in this experiment included
untreated cells, cells treated with naked pGFP, and cells treated with pGFP complexed
with PEI at a N/P ratio of 7:1. Cells were then incubated for 24 hours, at which point all
wells were washed three times with media and were left to incubate an additional 24
hours.
At 48-hours post-transfection, GFP-expressing cells were imaged using an
inverted fluorescent microscope. After imaging, cells were washed with PBS and
incubated for 10 minutes in 250 μL of 0.25% trypsin. 500 μL of media was then added to
each well, and samples were briefly triturated before being removed to Eppendorf tubes
for analysis by flow cytometry. Results were gated by size to eliminate cell fragments
and groups of clumped cells, and by fluorescence set as the lowest point at which
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untreated cells showed 0% transfection in order to control for low levels of auto
fluorescence.

4.5.2 Cytotoxicity of PgP complexed with pGFP
To determine the cytotoxicity of PgP as a vector for pDNA, a cytotoxicity study
was performed in parallel experiments to the transfection efficiency study outlined in
section 3.8.1. and using the same transfection procedure given above. MDA-MB-435
cells were used for this experiment as well, transfected with PgP/pGFP polyplexes
complexed at N/P ratios of 30:1, 45:1, and 60:1 in sterile deionized water, and control
groups once again included untreated cells, cells treated with naked pGFP, and cells
treated with pGFP complexed with PEI at a N/P ratio of 7:1.
Cell viability was then determined by MTT assay performed according to the
following procedure. At 48-hours post-transfection, all wells were rinsed three times with
media. Cells were then incubated for 4 hours at 37 °C in 500 μL of serum-free media and
120 μL of 2 mg/mL Thiazolyl Blue Tetrazolium Bromide (TBTB) in PBS. After
incubation, cells were rinsed with PBS and 1 mL of DMSO added to all wells. The plate
was wrapped in foil and placed on an orbital shaker for 10 minutes to allow for complete
dissolution of the formazan crystals formed during their incubation with TBTB. DMSO
was removed to a 96-well plate and the absorbance at 570 nm measured in triplicate
using a Biotek Synergy HT plate reader. Relative cell viability was calculated as Cell
Viability (%) = (OD570 (sample)/OD570 (control))*100
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4.6 Heparin Competition Assays
While the ability of PgP to successfully bind, protect, and deliver pDNA has been
previously established,132 this study was proposed in order to determine the binding
strength of PgP to siRNA relative to that of pDNA. 1% and 2% agarose gels were
prepared with a 12-well comb and used for pGFP and siMDR1, respectively, both stained
with 0.2% ethidium bromide. Polyplexes were prepared at N/P ratios of 30:1, 45:1, and
60:1 with either pGFP or siMDR1, controlling for 0.1 μg of nucleic acid per well.
Samples were then incubated for 30 minutes at 37 °C to allow stable and consistent
complex formation. Heparin was added to the complexed samples in varying
concentrations, measured by weight ratio of heparin to nucleic acid in the sample. After
the addition of heparin, samples were incubated for one hour at 37 °C and then loaded
into the gels using formaldehyde loading dye or 6x DNA loading dye. Samples were
electrophoresed at 80 V for 60 minutes, and visualized with the ChemiDoc-It system
using an ethidium bromide filter and UV illumination.

4.7 Knockdown Efficiency and Cytotoxicity of PgP/siMDR1 Complexes
4.7.1 Cytotoxicity of PgP/siMDR1 Complexes
In order to evaluate if PgP/siMDR1 complexes cause toxicity to cells, whether
due to the particle, the introduction of siMDR1, or by any other means, a cytotoxicity
study was performed. MDA-MB-435 ADR cells (6 x104 cells/well) were seeded into 24well plates containing complete media and cultured for 24 hours prior to transfection.
Following the previously outlined transfection procedure, PgP/siMDR1 complexes
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formed at N/P ratios of 30:1, 45:1, and 60:1 in sterile nuclease-free water were added to
wells with 500 μL of complete media. Control groups for this experiment included
untreated cells, and cells treated with Lipofectamine 3000 carrying siMDR1. Dose was
controlled for treatment groups by siMDR1 amount: 1 μg/well. One deviation from the
transfection procedure outlined in section 4.5.1, aside from the control groups and nucleic
acid use, was that the Lipofectamine 3000 treated groups were cultured for 48 hours in
transfection media as instructed by the manufacturer, rather than the sequential 24 hour
incubations in transfection media and normal media performed on all other groups.
Following the MTT protocol outlined in section 4.5.2, cells were rinsed with PBS thrice
at 48 hours post-transfection and incubated for 4 hours in serum-free media and TBTB
dissolved in PBS. Cells were rinsed three more times in PBS and 1 mL of DMSO added
to all wells. The plate was wrapped in foil and placed on an orbital shaker for 10 minutes
to allow for complete dissolution of the formazan crystals formed during their incubation
with TBTB. DMSO was removed to a 96-well plate and the absorbance at 570 nm
measured in triplicate using a Biotek Synergy HT plate reader. Relative cell viability was
calculated as Cell Viability (%) = (OD570 (sample)/OD570 (control))*100

4.7.2 MDR1 Silencing
The degree of MDR1 silencing by PgP-mediated transfection with siMDR1 was
quantified in MDA-MB-435 ADR cells. MDA-MB-435 ADR cells were transfected
using the same procedure as outlined in 4.7.1, in 24-well plates seeded at 6x104 cells/well
and cultured for 24 hours prior to transfection. Polyplexes were formed at N/P ratios of
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30:1, 45:1, and 60:1 in sterile nuclease free water and incubated at 37 °C for 30 minutes
to allow formation of stable complexes. Control groups included untreated cells and cells
treated with Lipofectamine 3000 delivering siMDR1. At 48-hours post-transfection, cells
were harvested and isolated for either protein or RNA, to evaluate the MDR1 expression
level by western blot in protein level and real-time PCR (RT-PCR) in mRNA level,
respectively.
i) Western blot
At 48 hours after transfection, cells were washed with PBS and then lysed with
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1%
SDS, and 1% triton-x) containing 0.1% Halt Protease & Phosphatase Inhibitor Cocktail
(see 3.1: materials), all chilled to 4 °C prior to addition into the well plate. Wells were
scraped using the rubber plunger of a 1 mL syringe, briefly triturated, and removed to
Eppendorf tubes which were then placed on ice for 10 minutes to allow complete cell
lysis. Samples were briefly vortexed at low speed and then centrifuged at 10,000 rpm and
4 °C for 15 minutes, after which samples were removed to new Eppendorf tubes without
disturbing the pellet formed during centrifugation. Concentration of the samples was
determined by BCA assay using the Pierce BCA Protein Assay Kit, performed according
to the manufacturer’s protocol. 10 μg of protein lysates from each sample were then
loaded into SDS-Page gels and run for 15 minutes at 150 V, followed by 90 minutes at
120 V once samples had entered the stacking gel. Proteins were then transferred to
Immuno-Blot Polyvinylidene fluoride (PVFD) membranes for one hour at 100V.
Membranes were then submerged in blocking solution (4% Bovine Serum Albumin
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(BSA) in Tris-HCl buffered saline with 0.1% Tween-20 (TBST)), for one hour at room
temperature on an orbital shaker at low speed. After blocking, primary antibody binding
was accomplished by incubating the membranes in blocking solution containing either
mouse monoclonal anti-MDR1 antibody (1:800 dilution) or mouse monoclonal anti-βactin antibody (1: 1,000) for 16 hours at 4 °C. Membranes were then thrice washed for 5
minutes in TBST and incubated in blocking solution containing horseradish peroxidase
(HRP) conjugated goat anti-mouse secondary antibody (1: 8,000) for one hour at room
temperature. Membranes were once again washed for 5 minutes in TBST three times
followed by a 5-minute incubation at room temperature with 1 mL of SuperSignal West
Pico Chemiluminescent Substrate. Membranes were then sealed in plastic wrap and
imaged using the ChemiDox-It system with no filter applied and an exposure time of 5
minutes.
ii) RT-PCR
At 48 hours post-transfection, cellular RNA was isolated and purified using the
RNeasy Mini Plus Kit according to the manufacturer’s protocol. Genomic DNA (gDNA)
was eliminated using the TURBO DNA-Free Kit, after which the concentration and
purity of RNA samples was determined by absorbance at 260, 280, and 320 nm measured
with a Take3 Micro-Volume Plate and a Biotek Plate Reader. 10 µg of each RNA sample
was then reverse transcribed into cDNA using the High-Capacity cDNA Reverse
Transcription Kit with MultiScribe Reverse Transcriptase according to manufacturer
instructions. RT-PCR was performed in duplicate for all samples using the Quantitect
SYBR Green PCR Kit, a Rotor Gene Q thermal cycler, and IDT custom forward and
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reverse primers for MDR1 and the endogenous control gene GAPDH. A RT-PCR
standard curve was generated using RNA samples isolated from untreated MDA-MB-435
ADR cells to determine the amplification efficiency of the target and reference genes,
calculated from the slope of the standard curve (CT vs. log(quantity)) with the equation e
= 10-1/slope and found to be within 0.05 of 100% efficient for both genes, with R2 values of
> 0.997. The cycle number at which the fluorescence detected was greater than the
threshold line of 0.02, or threshold cycle (CT), was determined for GAPDH and MDR1 in
all samples and relative mRNA expression of MDR1 calculated using the ΔΔCT method,
where ΔCT = CT (Target) - CT (Reference), ΔΔCT = ΔCT (Sample)-ΔCT (Control), and relative
expression (%) = 2-ΔΔCt. Controls for all samples run were prepared without reverse
transcriptase during reverse transcription (-RT) and used in all RT-PCR experiments as
negative controls to identify gDNA contamination, and each RT-PCR experiment
included a no-template control (NTC). Melt curve analyses were performed following
each run and indicated no formation of primer dimers, nonspecific binding, or other
potential sources of error in the procedure.

4.8 Doxorubicin Loading in PgP
To load doxorubicin (DOX) in PgP, the hydrophobic drug DOX was first
dissolved in methanol at varying concentrations and added to samples of 1 mg/mL PgP at
a 1:10 ratio (v/v), therefore the concentration of DOX in methanol was 10x the final
loading concentration used to calculate loading efficiencies and capacities. The samples
were shaken for 4 hours at room temperature, and left overnight to allow for methanol
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evaporation. After complete evaporation of methanol, sterile deionized water (DW) was
added to supplement water loss due to evaporation and the samples were briefly
centrifuged. Samples were then filtered using 0.2 μm PES membrane syringe filters.
Absorbance of the samples at 520 nm was measured using a Biotek Synergy HT
plate reader, and DOX concentration of each sample was calculated by Beer’s law. The
standard curve was made using doxorubicin-HCl (DOX-HCl) in deionized water in
concentrations ranging from 0.025-0.5 mg/mL and samples read were diluted with a
dilution factor of 5 to prevent detector saturation. Entrapment efficiency was calculated
as EE=drug loaded (weight)*100/total drug (weight). Loading capacity was calculated as
LC (%)=drug loaded (weight)*100/Nanoparticle (weight), used to quantify the drug
content of the particle irrespective of its presence in the medium.

4.9 Cytotoxicity of Doxorubicin-loaded PgP
The cytotoxicity of Doxorubicin-loaded PgP (DOX/PgP) was determined by MTT
assay performed on MDA-MB-435 ADR cells after treatment with DOX/PgP. Cells were
seeded in 24-well plates at a concentration of 6 x104 cells/well, using a working volume
(500 uL) of complete medium and incubated for 24 hours. Cell medium was then
replaced with RPMI 1640 cell medium supplemented with 10% FBS and 1% LGlutamine. DOX/PgP was prepared as outlined in section 4.8 at a loading concentration
of 1 mg/mL doxorubicin and diluted with DW to varying concentrations of DOX ranging
from 1-25 μM (determined by previously outlined loading study) and a final volume of
50 μL/well. Control groups consisted of untreated cells, cells treated with equivalent
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concentrations of DOX-HCl, and cells treated with equivalent concentrations of PgP
alone. Cells were then incubated for an additional 24 hours, at which point all wells were
rinsed three times with media. Cells were then incubated for 4 hours at 37 °C in 500 μL
of serum-free media and 120 μL of 2 mg/mL Thiazolyl Blue Tetrazolium Bromide
(TBTB) in PBS. After incubation, cells were rinsed with PBS and 1 mL of DMSO added
to all wells, and the plate was wrapped in foil and placed on an orbital shaker for 10
minutes to allow for complete dissolution of the formazan crystals formed during their
incubation with TBTB. DMSO was then removed to a 96-well plate and absorbance at
570 nm measured in triplicate using a Biotek Synergy HT plate reader. Relative cell
viability was calculated as Cell Viability (%) = (OD570 (sample)/OD570 (control))*100

4.10 Combinatorial Therapy of Doxorubicin and siMDR1 by PgP
To evaluate the synergistic effect of MDR1 gene knockdown and DOX treatment,
we performed 2 different treatment methods, 1) co-delivery of DOX/PgP/siMDR1 and 2)
sequential treatment of PgP/siMDR1 and then DOX/PgP.
i) Cytotoxicity of co-delivery of DOX/PgP/siMDR1 in MDA-MB-435 ADR cells
The cytotoxicity of co-delivered DOX and siMDR1 was determined by treatment of
MDA-MB-435 ADR cells with DOX-loaded PgP (2.36 μg DOX for N/P ratio of 30:1 and
3.54 μg DOX for N/P ratio of 45:1) complexed with siMDR1 (1 μg siMDR1 for N/P ratio
of 30:1 and 45:1). DOX/PgP/siMDR1 complexes were prepared by first loading DOX in
PgP according to the procedure outlined in section 4.8 using a DOX loading
concentration of 1 mg/mL in PgP (1 mg/mL) and confirmed by absorbance at 520 nm.
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DOX/PgP samples were then complexed with siMDR1 at N/P ratios of 30:1 and 45:1 in
sterile nuclease-free water and incubated for 30 minutes at 37 °C, prepared immediately
prior to addition into the wells. Cells were seeded 24 hours prior to transfection in 24well plates (6 x104 cells/well). Controls for this experiment included untreated cells, and
cells treated with PgP alone, DOX-HCl, DOX/PgP, PgP/siNT, PgP/siMDR1, and
DOX/PgP/siNT. Cells were incubated for 24 hours, at which point wells were rinsed and
replaced with complete media, followed by an additional 48-hour incubation. 72 hours
after treatment, cell viability was measured by MTT assay, using the same methods as
those outlined in chapter 4.5.2.
ii) Cytotoxicity of sequential treatment of PgP/siMDR1 and DOX/PgP
The cytotoxicity of sequential treatment of DOX and siMDR1 was determined by
treatment of MDA-MB-435 ADR cells with PgP/siMDR1 first and then treated with
DOX-HCl. PgP/siMDR1 polyplexes (1 µg siMDR1 for N/P ratios of 30:1 and 45:1) was
transfected in MDA-MB-435 ADR cells in parallel to the co-delivery study outlined
above using the same methods. At 48 hours after transfection, all cells were then treated
with DOX-HCl, at an equivalent dose to that of DOX loaded in PgP for the given N/P
ratio used (9 µM and 13.5 µM for N/P ratios of 30:1 and 45:1, respectively). After an
additional 24-hour incubation, a total of 72 hours after treatment with PgP/siMDR1
polyplexes, cell viability was measured by MTT assay, using the same methods as those
outlined in chapter 4.5.2.
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4.11 Statistical Analysis
Quantitative data is presented all figures as mean ± SEM. Statistical analyses
between two groups were performed with a Student’s t-test, and analysis among multiple
groups was performed using a one- way analysis of variance (ANOVA). Results were
considered statistically significant when P < α, where α = 0.001 for RT-PCR results, and
α = 0.05 for all other experiments. All calculations for statistical analysis were performed
using the Analysis ToolPak program within Microsoft Excel.
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CHAPTER 5
RESULTS

5.1 Transfection Efficiency and Cytotoxicity of PgP/pGFP Polyplexes
Qualitative analysis by fluorescent microscopy showed successful uptake of the
particle by the MDA-MB-435 ADR cells, indicated by the expression of GFP which is
visible in figure 3. As expected, no fluorescence was visible in cells treated with naked
pGFP, having no inherent mechanism to facilitate entry into the cytosol. Cells treated
with pGFP/PEI showed very little fluorescence in terms of both intensity and the number
of cells exhibiting GFP Fluorescence, due to its poor stability in serum conditions. Of the
cells treated with PgP, the N/P 60:1 and 30:1 groups appeared to have similar proportions
of cells producing GFP, however the fluorescing cells within the 60:1 treated groups
showed a markedly higher intensity of fluorescence than those treated with complexes
formed at N/P 30:1. The results, given in figure 4, are consistent with fluorescent
imaging, showing very low transfection in PEI and highest transfection in the 60:1 groups
and statistical significance between the PgP N/P 30:1 and 60:1 groups in both the wild
type and ADR cells at an alpha value of 0.05. Groups treated with naked pGFP showed
no significant transfection in comparison to untreated groups, reiterating the need for a
delivery system in transfection with pDNA.
Results of the cytotoxicity experiment, given in figure 5, showed minimal toxicity
in the groups treated with PgP at N/P ratio of 30:1, with a strong positive correlation
between the N/P ratio used and cytotoxicity in all PgP-treated groups. Actual percent
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Figure 3. Visualization of transfection by GFP expression in MDA-MB-435 Cells. Both Wild Type (left) and ADR
cells (right) were treated with naked pGFP (control), PEI (N/P 7:1) and PgP/pGFP complexed at N/P ratios of 30:1,
45:1, and 60:1. In these images, taken 48 hours after transfection, PgP is shown to successfully mediate delivery of
pDNA to the intracellular compartment for release within the cytosol.

viability for all ADR groups relative to the control were 105%, 92%, 77%, 70%, and 90%
for PEI 7:1, PgP 30:1, 45:1, and 60:1, and Lipofectamine 3000, respectively. A similar
trend was observed in the wild type groups, with cell viabilities of 98%, 80%, 65%, and
45% for PEI 7:1, PgP 30:1, 45:1, and 60:1, respectively. In summary, this study has
shown that PgP can be used for delivery of nucleic acid into the cytosol of drug resistant
human cancer cells such that they can then function, and that there is potentially an ideal
N/P ratio in which transfection efficiency can be maximized while mitigating any
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Figure 4. Transfection Efficiency of PgP/pGFP complexes in MDA-MB-435 ADR Cells. Measured by flow
cytometry in analysis of GFP expression 48 hours after transfection with naked pDNA, PEI (N/P 7:1), and PgP
(N/P 30:1 and 60:1). Data shown is mean ± SEM of three independent experiments (N=3) in which all groups were
run in triplicate. Significance was found for all PgP/pGFP groups compared to untreated cells, and significance
found between WT and ADR for PEI and PgP/pGFP 60:1 (P<0.05, Student’s t-test).

Figure 5. Cell Viability of MDA-MB-435 ADR cells 48 hours after treatment with PgP/pGFP. Relative Cell
Viabilities shown were determined via MTT assay and read by absorbance at 570 nm in 96-well plates. Groups
shown are (left to right) Untreated cells, PEI/pGFP at N/P ratio 7:1, PgP/pGFP at N/P ratio 30:1, PgP/pGFP at N/P
ratio 45:1, PgP/pGFP at N/P ratio 60:1, and pGFP loaded in Lipofectamine 3000. Data is given as mean ± SEM of
four independent experiments (N=4) performed in triplicate. Significant difference (P<0.05) was found between
WT and ADR cells in all PgP/pGFP groups.
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cytotoxic effect of the particle for use as a non-viral vector in therapeutic gene therapy
with siRNA.

5.2 Heparin Competition Assay
PgP has previously been shown to effectively mediate transfection in some cell
lines with pDNA,132 however existing research suggests that within the field of synthetic
carriers the ability of a vehicle to successfully deliver pDNA may not be as translatable to
RNA applications as previously thought.146 To that end, a heparin competition assay was
performed on PgP/pGFP and PgP/siMDR1 polyplexes to assess the binding strength of
siRNA relative to that of pDNA. Heparin, due to its strong negative charge, will compete
with nucleic acids present in the complex to electrostatically associate with amine groups
in the corona of the PgP micelles, ultimately causing nucleic acid to dissociate from the
complex when present in high enough concentration. For this study, PgP was complexed
with either pGFP or siMDR1 at N/P ratios of 30:1, 45:1, and 60:1 and incubated with
varying concentrations of heparin, measured here by their weight ratio (WR) to the
nucleic acid present, and compared to naked siMDR1 or pGFP corresponding with the
complex used. Imaging of the gels after electrophoresis show that PgP/pGFP complexes
consistently begin to dissociate at much higher weight ratios of heparin, indicating a
lower competitive stability in siMDR1-containing complexes. Displacement of pGFP can
be seen occurring at WRs of 6:1, 9:1, and 12:1 for complexes formed at N/P ratios of
30:1, 45:1, and 60:1, respectively, while in PgP/siMDR1 complexes dissociation is seen
much earlier, at WRs of 3:1, 4:1, and 6:1. PgP/pGFP complexes at N/P 30:1. Although
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displacement of siMDR1 begins much earlier than pGFP in PgP complexes, partial
displacement of siMDR1 can be seen over a much larger range than in pGFP groups.
Complete dissociation (as can be referenced by the naked nucleic acid group in each
image) of siMDR1 from PgP only occurs after a large range of partial displacement, at
weight ratios of 5:1, 9:1, and 10:1 – much closer to those at which pGFP completely
dissociates.
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Figure 6. Heparin competition assay. Competitive dissociation of PgP/pDNA in the presence of heparin at varying
weight ratios (Heparin/Nucleic acid ratio). Samples shown are (left to right) naked nucleic acid, followed by polyplex
samples incubated in increasing ratios (w/w) of heparin to nucleic acid in the sample. A) PgP/pGFP (N/P 30:1) B)
PgP/siMDR1 (N/P 30:1) C) PgP/pGFP (N/P 45:1) D) PgP/siMDR1 (N/P 45:1) E) PgP/pGFP (N/P 60:1) F)
PgP/siMDR1 (N/P 60:1)

5.3 PgP-Mediated Delivery of siMDR1
In order to assess the ability of PgP to deliver siMDR1 to cells and that the siRNA
delivered succeeds in silencing the gene coding for P-glycoprotein (MDR1), MDA-MB435 ADR cells were transfected with PgP/siMDR1 complexes formed at N/P ratios of
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30:1, 45:1, and 60:1, and examined for silencing of MDR1 at the mRNA and protein
levels as well as the cytotoxicity of the doses used to produce samples for these
knockdown experiments. To assess MDR1 expression on the protein level, the protein
levels of each group determined by BCA assay, and each sample analyzed by western
blotting for MDR1 expression with β-actin chosen as an endogenous control for
normalizing protein level per lane (MDR1 ~170 kDa, β-actin ~42 kDa). Visually, MDR1
protein expression (shown in figure 7) in the control band appears much higher than in
the knockdown groups, and when normalized the relative expression of MDR1 was found
to be at 52%, 23%, 21%, and 29% when compared to the control for PgP 30:1, 45:1,
60:1, and Lipofectamine 3000, respectively. Silencing of MDR1 at the mRNA level was
assessed by RT-PCR, and results given in figure 8. The expression of mMDR1 was
normalized using GAPDH as an endogenous control and within 0.5 Ct of the GAPDH CT
value found of the control group. All groups showed significant knockdown in
comparison to untreated cells, with PgP complexed at N/P ratios of 30:1, 45:1 and 60:1
showing relative gene expressions of 76%, 65%, and 33%, respectively. Cytotoxicity of
these groups was assessed via MTT assay, the results of which are shown in figure 9. In
consideration of both the silencing and cytotoxicity results, N/P 45:1 PgP was selected to
move forward with in future studies.
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Figure 7. Western blot analysis of MDR1 expression following treatment by
PgP/siMDR1. Results reflect MDR1 protein levels in MDA-MB-435 ADR cells at 48
hours after treatment with siMDR1 containing complexes of PgP prepared at N/P
ratios of 30:1, 45:1, and 60:1, with untreated cells as the negative control (left) and
Lipofectamine 3000 used as a positive control (right). Β-actin was used to normalize
results for densitometric analysis

Figure 8. Relative expression of MRD1 after knockdown by PgP/siMDR1 polyplexes by RT-PCR. Results of RTPCR analysis of MDA-MB-435 ADR cells harvested 48 hours after treatment. Samples shown were (from left to
right) untreated, treated with PgP/siMDR1 polyplexes complexed at N/P ratios of 30:1, 45:1, and 60:1, and
siMDR1 loaded in Lipofectamine 3000. GAPDH was used as an endogenous control. Data is given as mean ± SEM
of four independent experiments performed in triplicate where *P<0.0001, (student’s t-test) in comparison to
untreated cells.
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Figure 9. Cytotoxicity of MDA-MB-435 ADR Cells After Treatment with PgP/siMDR1. Relative cell viability was
determined by MTT assay with untreated cells, cells treated with PgP/siMDR1 complexed at N/P ratios of 30:1,
45:1, and 60:1, as well as siMDR1 loaded into Lipofectamine 3000. Data shown is mean ± SEM of three
independent experiments performed in triplicate. Results were found to be significant (P<0.05) by one-way
ANOVA.

5.4 Doxorubicin Loading in PgP
Based on the intercalating mechanism through which it functions, a means of
intracellularly delivery can significantly improve the efficacy of Doxorubicin. Given the
established ability of PgP to deliver pDNA into the cytosol of cancer cells, the capacity of
PgP as a carrier for DOX was examined. As shown in figure 10, the ability of PgP to
entrap doxorubicin, given by loading capacity, showed a clearly defined positive
correlation with the total amount added. However, the entrapment efficiency declined
significantly as a result. No steep decline in entrapment efficiency was observed for the
concentrations of DOX used that would indicate an approaching maximum capacity of
PgP, however the amount of DOX that could be loaded in this analysis was constrained
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by the solubility limit of DOX in methanol used in the loading process. Given these
results, PgP has shown it can be successfully loaded with DOX, and based on the
encapsulation efficiency of DOX/PgP as well as the amount of PgP required for effective
transfection, an initial DOX concentration of 1 mg/mL was selected as the loading
parameter for further studies with PgP/DOX.
Cytotoxicity of DOX-loaded PgP was determined by MTT assay, in comparison
to untreated cells, as well as cells treated with PgP alone or DOX-HCl. As shown in
figure 10, a clear increase in cytotoxicity is observed in DOX/PgP treated groups,
however the relative cell viabilities of the groups tested leave it unclear if this increase is
due to any synergistic effect of the PgP such as an improved efficacy due to intracellular
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Figure 10. Doxorubicin Loading in PgP. (Left) Entrapment Efficiency of Doxorubicin in PgP, calculated as the
amount of drug loaded divided by the total drug added (Right) Loading Capacity of Doxorubicin in PgP, the actual
ability of the particle to entrap DOX, and calculated as the Loading= loaded drug (weight)*100/PgP (weight). Data
is given as mean ± SEM of three independent studies performed in triplicate.
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Figure 11. Cytotoxicity of DOX-Loaded PgP Micelles. Doxorubicin was loaded into PgP micelles with an initial
concentration of 1 mg/mL and loading efficiency determined at 42%. This value was used in calculating equivalent
dose of DOX-HCl, taking into account the difference in molecular weight between DOX freebase and the HCl
formulation. PgP dose used was equal to the dose of DOX-loaded PgP. Results are given as mean ± SEM of three
independent experiments performed in triplicate.

5.5 Combinatorial Therapy of Doxorubicin and siMDR1 by PgP
To determine the practical efficacy of the fully assembled DOX/PgP/siMDR1
particle, Cytotoxicity studies were performed using MTT assays of MDA-MB-435 ADR
cells treated both concurrently and sequentially with PgP/siMDR1 and Doxorubicin,
using complexes prepared at N/P 45:1. For assessing the ability of co-delivered siMDR1
and DOX to treat drug resistant cells, groups were treated with DOX-HCl alone, PgP and
DOX-loaded PgP complexed with siMDR1, and formulations of PgP or DOX-loaded PgP
either alone or complexed with non-targeting siRNA (siNT). As seen in Figure 12, all
groups treated with doxorubicin loaded PgP showed significant cytotoxicity over other
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groups, with a slight decrease in cytotoxicity observed in the DOX/PgP/siNT group
compared to uncomplexed DOX/PgP. A significant increase in cytotoxicity was seen in
the DOX/PgP/siMDR1 groups in comparison to non-targeting groups (DOX/PgP/siNT),
however the greatest contributor of toxicity to treated groups appears to be doxorubicin
delivery by PgP.
In sequentially treated groups, treated with DOX/PgP (13.5 μM DOX) 48 hours
after an initial transfection with PgP/siRNA, cytotoxicity was determined by MTT assay,
the results of which are shown in figure 13. As with the co-delivery study, significantly
higher cytotoxicity was observed in the PgP/siMDR1 groups compared to non-targeting
(PgP/siNT) groups, however once again treatment with DOX/PgP seems to be the
greatest contributor to toxicity even in this drug-resistant cell line. Given the static nature
of the in vitro environment as well as the inherently time-dependent nature of siRNAmediated gene silencing, in vivo studies may be necessary to determine the optimal time
frame of re-sensitization in cancer populations. Despite this, even the results of shortterm studies have demonstrated the ability of PgP in mediating both MDR1 knockdown
as well as intracellularly delivering doxorubicin, establishing its capacity as a delivery
vehicle for both DOX and siRNA, and justifying its potential candidacy for further
characterization in vivo.
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Figure 12. Cytotoxicity of PgP mediating Co-delivery of doxorubicin and siMDR1. MDA-MB-435 ADR cells were
treated with the given groups, with all PgP doses reflecting complexation at a N/P ratio of 45:1. All groups were
analyzed at 48-hours post treatment via MTT assay. Data is shown as mean ± SEM, with significance found
between DOX/PgP/siNT and DOX/PgP/siMDR1 groups (P<0.05) by t-test.

Figure 13. Cytotoxicity of sequential treatment with PgP/siMDR1 and Doxorubicin HCl. MDA-MB-435 ADR cells
were treated with the shown groups, and 48 hours later groups indicated by ‘+DOX-HCl’ were given a second
treatment of 13.5 μM Doxorubicin HCl. Cytotoxicity of all groups was then assessed by MTT assay at 72 hours
after initial treatment. Data is given as mean ± SEM. Significance was found between PgP/siNT and PgP/siMDR1
groups given a secondary treatment of DOX/PgP by t-test (P<0.05).
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CHAPTER 6
DISCUSSION

The goal of this project was to develop and characterize the novel polymeric
micelle developed by this lab, PgP, for its application and utility in mitigating multidrug
resistance in metastatic breast cancer. Establishing the safety and utility of its use in both
doxorubicin and siMDR1 delivery could prove relevant in treatment of triple-negative
breast cancer, such that it could improve the efficacy of normal treatment with
chemotherapeutics of the anthracycline class characterized by their hydrophobicity and
intercalating mechanism of function. Improving the efficacy of these drugs would result
in a lower minimal therapeutic dose and decrease both the risks of systemic cytotoxicity
they present as well as the rate at which drug resistance is developed in treated cancer
populations due to the inherently cyclic nature of treatment with these drugs. Ultimately
should these improvements be translated to clinical application they could serve to
improve treatment in terms of both safety and patient outcomes.
In evaluating the results of the experiments listed in this study, a few advantages
and shortcomings in the use of PgP as a delivery vehicle for doxorubicin and siRNA that
should be addressed. PgP was first examined for its ability to deliver pDNA in such a
way that it could then be functionally expressed by transfected cells. Results of these tests
proved PgP to be an effective vector for this application, however the trade-off between
maximizing particle efficacy and minimizing treatment toxicity is immediately apparent.
While increases of dose and N/P ratio of the polyplex did show a positive correlation to
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transfection efficiency in these experiments, the increase was not as linearly correlated as
could be expected – likely a result of the increase in cytotoxicity arising from the increase
in both dose and particle surface charge. Transfection efficiency of complexes formed
with pDNA was also observed to be lower than initially hoped, however not to a degree
that would eliminate PgP as a promising candidate for siRNA delivery. While a vector’s
ability to transfect cells with pDNA has been a widely used method of determining its
capacity for use in RNAi applications, pDNA and siRNA have been shown to behave
very differently when interacting with cationic DDVs, as well as their complex’s
subsequent interactions in the biological environment.146 The implications that this
difference in behavior between pDNA and siRNA complexed particles could have for
this project’s goals with PgP as a delivery vehicle were unclear, however, as the nature
and significance of this difference seems largely dependent on the particle being
examined and its individual charge and complexation to nucleic acid. With that in mind,
the binding strength of PgP to siRNA relative to that of pGFP was examined at various
N/P ratios through heparin competition, with surprising results; showing stable binding at
significantly higher heparin concentrations in the pGFP-bound micelles, while exhibiting
similar points of complete dissociation.
Heparin competition revealed siRNA-bound complexes to have a lower overall
binding strength to PgP than pGFP-containing polyplexes, although dissociation of
nucleic acids within the complex through competition with other charged particles in
solution occurred over a much larger range of concentrations than the pGFP-bound
groups, which showed a nearly binary relationship when it comes to competition-driven
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dissociation with exception to complexes formed at very high N/P ratios. This would
imply that PgP/siRNA complexes may show the same drastic increase in efficacy at high
N/P ratios for knockdown that the PgP/pDNA complexes did in transfecting GFP
expression, however, as their mechanisms of function within the cytosol differ, it is
unclear to what degree the actual amount of siRNA delivered to a cell may impact target
gene expression.
siMDR1 complexes consistently showed dissociation at much lower weight ratios
of heparin, despite the fact that nucleic acid loading was controlled for all samples by
mass, making the overall charge of the siRNA added slightly stronger than that of the
pDNA due to the lower molecular weight of RNA base pairs. Additionally, the results of
the heparin competition would indicate that despite the significantly smaller size of the
siRNA, it primarily binds to the surface of the micelle in the same manner as pDNA,
rather than interpenetrating the PEI layer of the PgP micelles to associate with deeper
amine groups, although confirmation of this through AFM or SEM would be necessary to
confirm this indication.
This test was followed by in depth assessment of MDR1 knockdown by
PgP/siMDR1 treated groups. RT-PCR and western blot testing both showed significant
silencing of the MDR1 gene on both a mRNA and protein level at 48 hours after
treatment, to levels much more significant than those given by pDNA transfection
studies. While unexpected, this is not unprecedented as PEI and its derivatives have
shown in previous studies (albeit unreliably) for improved performance as a vehicle for
siRNA over pDNA.146
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Having established the ability of PgP to mediate silencing of the gene coding for
P-glycoprotein (MDR1), the capacity of PgP as a carrier for the hydrophobic drug
doxorubicin was then examined. PgP was quickly determined to be capable of loading
doxorubicin, although its release over time in serum conditions would be an interesting
relationship to quantify, as its stability in PgP micelles in water alone would not be
representative of its behavior in vivo due to the relative insolubility of doxorubicin in
water and the abundance of hydrophobic compounds capable of acting as a solvent to the
drug in biological conditions. The loading capacity and entrapment efficiency of
doxorubicin in PgP showed normal behavior, although this relationship is likely
dependent on the formulation of PgP apropos its PLGA chain length. With the 12 kDa
PLGA chain present in the formulation of PgP used in this study, the maximum loading
capacity of PgP was limited by the solubility of doxorubicin in the methanol used in the
loading process rather than the actual solubility of doxorubicin in PgP. This could be
overcome through the use of alternative solvents in loading, however based on the results
found and the potential for PgP degradation by stronger organic solvents, the model used
was found to be acceptable for this study. In consideration of PgP toxicity required dose,
as well as the loading data with regards to the cost and dosage of doxorubicin in clinical
applications, loading conditions of 1 mg/mL initial doxorubicin and PgP concentrations
were selected for all subsequent studies involving DOX-loaded PgP. The relative
cytotoxicity of DOX/PgP in comparison to DOX-HCl and PgP alone showed that
delivery mediated by PgP micelles improved efficacy of the drug over the salt
formulation, although at high doses beyond what would realistically be used for PgP
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showed that it is likely the primary source of toxicity, as seen by the parallel decrease in
cell viability exhibited by PgP and DOX/PgP groups that was not reflected in similarly
increasing doses of DOX-HCl. To confirm the actual mechanism of toxicity in doxloaded PgP, whether a function of PgP exposure, its combination with doxorubicin, or
due to intracellular delivery of DOX, a TUNEL assay may be incorporated into future
studies. Since the function of DOX, like other anthracyclines, produces double stranded
DNA breaks in affected cells,147 TUNEL may be useful in differentiating which of the
possible factors contribute most heavily to the observed increase in cytotoxicity by
DOX/PgP treatments.
The results of the in vitro studies would, at this point, merit progression to in vivo
characterization of its biocompatibility and antitumor effects, however both time and
fiscal restraints dictated further in vitro examination into the practical advantages of codelivering siMDR1 and doxorubicin. While the DOX/PgP/siMDR1 treated groups
showed radically lower cell viability than those treated with equivalent doses of DOXHCl, this was likewise reflected in both the non-targeting groups (DOX/PgP/siNT) and
the unbound DOX/PgP groups, prompting us to consider the time-dependent nature of
RNAi-mediated gene silencing. The effects of sequential treatment with PgP/siMDR1
followed by doxorubicin-HCl was examined, and these results did show significant
cytotoxicity of the siMDR1-treated cells in comparison with non-targeting groups,
however not to the scale or degree expected given the knockdown results. While this
could indicate the need to address another mechanism of resistance, such as bcl-2
dependent resistance, with siRNA in conjunction to the multidrug resistance mediated by
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P-glycoprotein, it may simply represent the limitations of in vitro analysis of the particle
at this stage. Given the static nature of the in vitro studies available to this lab, a more
translatable model may be needed. Additionally, determining the time frame and relevant
toxicities of optimum treatment may require a more complex model when considering the
time frame of transfection and siRNA-mediated gene silencing. While mRNA levels will
decrease within 24 hours of siRNA-mediated gene silencing, maximum silencing will
often be reached at a later point, usually sometime between 24 and 48 hours following
transfection. Functional protein levels, being further downstream, will take even longer to
reflect changes in RNA expression and are heavily dependent on the nature of the protein
in question and its stability within the experimental system.
Certainly, based on the ability of PgP/siMDR1 complexes to facilitate knockdown
of MDR1, as well as its ability to intracellularly delivery doxorubicin, PgP shows
potential as a vehicle for mediating multidrug resistance in cancer. Following in vivo
characterization, modifying the siRNA target to alternative or additional genes
responsible for drug resistance such as those in the bcl-2 resistance pathway, or further
downstream the pump-dependent (MDR1) pathway may serve to improve treatment
efficacy. Including siRNA targeting genes responsible for other proteins essential in
metastatic site development such as VEGF or HIF-1α (critical in angiogenesis and
directing metastatic proliferation) could also serve to impede proliferation of nontransfected cells within the tumor or pre-tumor environment. Another potential
modification to the vector that could be investigated is conjugation to a targeting moiety.
Currently, PgP micelles remain a 1st generation nanoparticle in that they contain no
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mechanism for specificity beyond passive targeting via the EPR effect. Potential
mechanism for targeting could include conjugation to growth factors matched to
upregulated receptors in target cancer populations (2nd gen.), or even conjugation to
specific antibodies targeting cancer cells (3rd gen.). One potential setback to consider in
this modification would be the proximity of a given targeting moiety to the charged PEI
corona of the micelles, therefore potential implementation of a hydrophilic spacer should
be considered as well – such as polyethylene glycol or other similar groups. Lastly,
complexation with siRNA supramolecular assemblies could also prove to act
synergistically with their previously established improvements on traditional siRNA in
terms of functionality,148 although this is purely speculative and would require additional
characterization of the complex, as incorporation of these structures may impact the
polyplex morphology, charge, or behavior in unforeseen ways as a result of their size and
flexibility, similarly to the differences in behavior observed in pDNA and siRNA-bound
complexes.
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CHAPTER 7
CONCLUSIONS
In conclusion, PgP has been definitively proven to effectively complex with
siRNA and mediate successful delivery into the cytosol of MDA-MB-435 ADR cells. In
comparison to PEI it has shown to be drastically more effective in serum conditions,
making it much more relevant to therapeutic applications. While moderate cytotoxicity
has been observed in higher N/P ratio complexes, those formed at N/P 45:1 and 30:1
show acceptably low cytotoxicity to justify further assessment in vivo. Moreover,
PgP/siMDR1 complexes have been shown to significantly reduce expression of MDR1 at
the mRNA level in vitro, with reductions as high as 67% observed in the N/P 60:1
complexes. In terms of its ability to deliver doxorubicin, PgP has shown to be an
effective carrier of the drug and even improve efficiency of the drug in clinically relevant
doses. The process of loading is simple and rapid, and compatible with 0.2-micron filter
purification.
Overall, PgP has shown to be a promising vector for siRNA delivery in drug
resistant cancer cells, and further development in terms of its conjugation with a targeting
moiety may result in a clinically relevant vector for not only treatment of multidrug
resistance, but a range of applications within the field of gene therapy.
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